Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)

NCT00536380 | Completed Phase 4 Results

• 1 other identifier: P04849
• Study Type: interventional
• Target: 314
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will investigate the effectiveness of desloratadine at doses higher (10 mg and 20 mg) than currently approved (5 mg) for the treatment of chronic idiopathic urticaria. Subjects with chronic urticaria who are currently taking a second generation antihistamine will be treated with desloratadine (5, 10, or 20 mg) for 28 days.

Conditions

Chronic Idiopathic Urticaria

Outcome Measures

Primary Outcomes (1)

• Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg

  The UAS is a composite diary-recorded score. The diary recorded scores included wheal score and pruritus score with numeric severity intensity ratings of 0 = none to 3 = intense. The scoring was to be done twice daily within one hour of arising and in the evening, approximately 12 hours later. Scoring was "reflective", covering the 12-hour period since the previous recording. The daily UAS is the average of the morning and evening scores. The final week by definition was the terminal week. It was the last week participants stayed for the treatment period.

  Baseline and 4 treatment weeks

Study Arms (3)

5-mg Desloratadine

EXPERIMENTAL

5-mg Desloratadine once daily

Drug: 5-mg Desloratadine

10-mg Desloratadine

EXPERIMENTAL

10-mg Desloratadine once daily

Drug: 10-mg Desloratadine

20-mg Desloratadine

EXPERIMENTAL

20-mg Desloratadine once daily

Drug: 20-mg Desloratadine

Interventions

5-mg Desloratadine DRUG

5-mg desloratadine tablets, once daily for four weeks.

Also known as: SCH 34117, Clarinex, Aerius

5-mg Desloratadine

10-mg Desloratadine DRUG

10-mg desloratadine tablets, once daily for four weeks.

Also known as: SCH 34117, Clarinex, Aerius

10-mg Desloratadine

20-mg Desloratadine DRUG

20-mg desloratadine tablets, once daily for four weeks.

Also known as: SCH 34117, Clarinex, Aerius

20-mg Desloratadine

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must satisfy the following criteria before being enrolled/randomized into the study.
• Subject must demonstrate willingness to participate in the study.
• Subject must be 18 to 75 years of age, of either gender, and any race.
• Subject must have had this episode of chronic idiopathic urticaria for at least 6 weeks or more, and has been dosing with a "2nd generation antihistamine (AH)" for 2 weeks or longer, and
• Subject's current episode of urticaria is sufficiently symptomatic at the Screening Visit to qualify for this study, in the opinion of the investigator.
• Subject has a Baseline Week (entry period) UAS between 10 and 30 inclusive.
• Patient must understand and be willing to assess and record symptom scores.
• Has voluntarily signed a written informed consent.
• Subjects must confirm that all prior medication washout times have been observed.
• Subject must confirm that he/she is practicing adequate contraception:
• Female volunteers of childbearing potential (including women who are less than 1 year postmenopausal and women who will be sexually active during the study) must agree to use a medically accepted method of contraception or be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 30 days after stopping the medication. Women who are postmenopausal for \>1 year (i.e., women who have experienced 12 consecutive months of amenorrhea) will be exempted from the use of contraception during the study. Nonsterile or premenopausal female subjects must be using a medically accepted method of birth control, ie, double-barrier method (eg, male or female condom and spermicide), oral contraceptive, Depo-Provera, NuvaRing, contraceptive transdermal patch, etc, for female subjects of childbearing potential prior to screening and during the study. Women of childbearing potential should be counseled in the appropriate use of birth control while in the study. Vasectomy or tubal ligation is considered a single barrier. Women who are not currently sexually active must agree and consent to use one of the above-mentioned methods if they become sexually active while participating in the study.
• If subject is a female volunteer of childbearing potential, she must have a negative urine pregnancy test at Screening/Visit 1.
• Subjects must be free of any clinically relevant disease other than chronic idiopathic urticaria (CIU) that would, in the principal investigator's and/or sponsor's opinion, interfere with the conduct of the study or study evaluations.
• Subjects must be able to adhere to the dosing and visit schedules and agree to record symptom severity scores, medication times, concomitant medications, and adverse events (AEs) accurately and consistently in a daily diary.

You may not qualify if:

• Is a female who is pregnant, or intends to become pregnant during the study.
• Is nursing, or intends to be nursing during the study or within 90 days after study completion.
• Has not observed the designated washout periods for any of the prohibited medications.
• Has used any investigational product within 30 days prior to enrollment.
• Have any of the following clinical conditions:
• Symptomatic seasonal or perennial allergic rhinitis.
• Asthma not controlled by short-acting beta-2 agonists used as necessary.
• The presence of permanent severe diseases, especially those affecting the immune system, except urticaria.
• The presence of a permanent gastrointestinal condition which may influence the oral therapy (chronic diarrhea diseases, congenital malformations or surgical mutilations of gastrointestinal tract).
• History of/or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia.
• History of/or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy.
• Evidence of/or a history of significant renal disease.
• Evidence of/or a history of significant hepatic disease.
• Presence of cancer which requires chemotherapy or radiation therapy.
• Presence of glaucoma.

Sponsors & Collaborators

• Organon and Co: lead

MeSH Terms

Conditions

Chronic Urticaria

Interventions

desloratadine

Condition Hierarchy (Ancestors)

Urticaria; Skin Diseases, Vascular; Skin Diseases; Skin and Connective Tissue Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Limitations and Caveats

Due to poor enrollment (even after extending the enrollment period), only 314 participants (not 600 participants) were randomized to the study and hence the study was inconclusive due to the lacking of statistical power and robustness.

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck, Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 26, 2007
• First Posted: September 27, 2007
• Study Start: September 1, 2007
• Primary Completion: April 1, 2009
• Study Completion: April 1, 2009
• Last Updated: May 23, 2024
• Results First Posted: May 3, 2010

Record last verified: 2022-02

Data Sharing

• IPD Sharing: Will not share